ISA Pharmaceuticals B.V. is a clinical-stage immunotherapy company developing rationally designed, fully synthetic immunotherapeutics against cancer and persistent virus infections. The Company has built a proprietary immunotherapy platform based on its Synthetic Long Peptide (SLP®) concept and its AMPLIVANT® technology. SLP® immunotherapies are designed to fully harness and direct the body’s own defense mechanisms towards fighting the disease, either alone or in combination with existing therapies.
ISA has established its pipeline based on mechanistic insights of the actions of its targeted immuno-therapeutics in patients. Various clinical trials up to completion of Phase II have demonstrated the safety, tolerability and clinical efficacy of SLP® compounds (proof-of-concept).